The Pharma Letter1d
ICER seeks to judge value of Trelegy and Breo Ellipta in COPD
The Institute for Clinical and Economic Review (ICER) has published a special report on chronic obstructive pulmonary disease (COPD) therapies as part of the Centers for Medicare & Medicaid Services ...
BMJ2d
Real-world evidence is a vital tool for informing treatment strategies in chronic obstructive pulmonary disease
The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...
The American Journal of Managed Care1y
Leveraging GOLD Guidance and Value-Based Strategies in the Management of COPD
The GOLD 2023 and 2024 reports recommend that health professionals consider triple therapy (TT) entailing combined use of a long-acting β 2 agonist (LABA), a long-acting muscarinic antagonist ...
Healthline2y
Trelegy Ellipta Side Effects and Tips for Managing Them
Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) can cause side effects that range from mild to serious. More common side effects include headache and ...